Status:
UNKNOWN
Qingkailing Injection Versus Puerarin Injection on Withdrawal Rate of Corticosteroids in Patients With Active Rheumatoid Arthritis
Lead Sponsor:
Chengdu PLA General Hospital
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the effect of Qingkailing injection versus Puerarin injection on withdrawal rate of corticosteroids in patients with active rheumatoid arthritis.
Eligibility Criteria
Inclusion
- with active RA
- without taking any other medication for the treatment of active RA in at least 4 last weeks
- aged from 18 to 75 years
- without conflict to the written, informed consent signed prior to the enrollment.
Exclusion
- being included in other clinical trial within the last 4 weeks
- with abnormal liver or kidney function (more than 1 time above the high normal)
- with serious cardiovascular disease
- with hematologic disease
- being in pregnancy, lactation period or under a pregnancy plan
- with severe gastrointestinal disease
- with contraindication or being allergic to the test drugs
- being under the treatment of drugs within 1 previous week, that might affect the results of the trial, such as non-steroidal anti-inflammatory drugs, steroidal anti-inflammatory drugs, immunosuppressants, anti-ulcer drugs
- being not compatible for the trial medication, or other circumstances at the discretion of investigators
- without legal capacity or only with limited legal capacity.
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT02264301
Start Date
August 1 2014
End Date
December 1 2017
Last Update
April 4 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General Hospital of Chengdu Military Area Command PLA
Chengdu, China, 610083